Taking an important step toward the development of a product to prevent HIV infections associated with unprotected anal sex, researchers on October 2 announced the launch of a global Phase II clinical trial of a potential rectal microbicide. The trial, led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), is testing the rectal use of a reduced glycerin gel formulation of the antiretroviral drug tenofovir. The Fenway Institute is one of 8 study sites worldwide that will be enrolling study participants. Known as MTN-017, the Phase II study will enroll 186 HIV-negative men who have sexRead More
Subscribe To Fenway Focus
Fenway Health has served the LGBT community, those affected by HIV, and our other members of our community in Boston’s Fenway neighborhood and beyond for the last 40 years. Learn more about Fenway Health; our research arm, The Fenway Institute; and the Sidney Borum, Jr. Health Center, which provides safe, non-judgmental care for young people ages 12–29 who may not feel comfortable going anywhere else.
Affordable Care Act AIDS AIDS2012 AIDS Action Committee AIDS Walk Boston behavioral health bisexual Construction Update Events Fundraisers Gender identity Harbor to the Bay Health care Health Disparities HIV HIV/AIDS HIV/AIDS Policy HIV prevention HIV Research HIV testing International AIDS Conference Lesbian health LGBT advocacy LGBT Aging Project LGBT health LGBT Health Research LGBT seniors LGBT Youth Mentions in the news men who have sex with men National LGBT Health Education Center news Pre-Exposure Prophylaxis PrEP The Fenway Institute trans Transgender Transgender Awareness Week Transgender Health Trans Health Trans Women Health Violence Recovery Program Women's Health Young Leaders Council young people